Cadence Capital Management Cut By $395,010 Its Bristol Myers Squibb Co (BMY) Position; Durect (DRRX) Has 1.48 Sentiment

November 15, 2017 - By Adrian Erickson

Cadence Capital Management Llc decreased Bristol Myers Squibb Co (BMY) stake by 3.56% reported in 2017Q2 SEC filing. Cadence Capital Management Llc sold 7,182 shares as Bristol Myers Squibb Co (BMY)’s stock declined 1.04%. The Cadence Capital Management Llc holds 194,432 shares with $10.83 million value, down from 201,614 last quarter. Bristol Myers Squibb Co now has $99.66 billion valuation. The stock declined 0.59% or $0.36 reaching $60.89 per share. About 129,174 shares traded. Bristol-Myers Squibb Co (NYSE:BMY) has declined 23.19% since November 15, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Durect Corporation is a biopharmaceutical firm with research and development programs. The company has market cap of $132.95 million. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. It currently has negative earnings. The Company’s other product candidates include POSIMIR , REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR opioid (hydromorphone) and SABER ophthalmic.

Analysts await DURECT Corporation (NASDAQ:DRRX) to report earnings on March, 13. They expect $-0.05 EPS, up 16.67% or $0.01 from last year’s $-0.06 per share. After $0.04 actual EPS reported by DURECT Corporation for the previous quarter, Wall Street now forecasts -225.00% negative EPS growth.

About 40,227 shares traded. DURECT Corporation (DRRX) has risen 7.89% since November 15, 2016 and is uptrending. It has underperformed by 8.81% the S&P500.

Gagnon Securities Llc holds 0.56% of its portfolio in DURECT Corporation for 1.28 million shares. Ingalls & Snyder Llc owns 6.42 million shares or 0.54% of their US portfolio. Moreover, Ironwood Investment Management Llc has 0.5% invested in the company for 440,945 shares. The New York-based 683 Capital Management Llc has invested 0.49% in the stock. Kings Point Capital Management, a New York-based fund reported 655,000 shares.

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 67 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Bristol-Myers Squibb Co (NYSE:BMY) has “Underweight” rating given on Friday, December 18 by Atlantic Securities. Barclays Capital maintained it with “Equal Weight” rating and $70 target in Tuesday, December 1 report. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Neutral” rating by Credit Suisse on Friday, October 27. On Wednesday, October 25 the stock rating was maintained by Citigroup with “Buy”. The stock has “Buy” rating by UBS on Friday, April 29. The firm has “Hold” rating by Credit Suisse given on Wednesday, August 16. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Market Perform” rating by BMO Capital Markets on Wednesday, April 5. The stock of Bristol-Myers Squibb Co (NYSE:BMY) has “Hold” rating given on Monday, August 14 by Cowen & Co. The stock of Bristol-Myers Squibb Co (NYSE:BMY) has “Sell” rating given on Monday, June 5 by BMO Capital Markets. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, August 5.

Analysts await Bristol-Myers Squibb Co (NYSE:BMY) to report earnings on January, 25. They expect $0.67 EPS, up 6.35% or $0.04 from last year’s $0.63 per share. BMY’s profit will be $1.10B for 22.72 P/E if the $0.67 EPS becomes a reality. After $0.75 actual EPS reported by Bristol-Myers Squibb Co for the previous quarter, Wall Street now forecasts -10.67% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Adrian Erickson




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: